A comprehensive view of Phase 2 Trial. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Moderna and Merck announce mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination With KEYTRUDA pembrolizumab, was granted breakthrough therapy designation by the FDA for adjuvant treatment of patients with high-risk melanoma
Published: February 23, 2023 by Moderna Inc.
Pfizer, Biontech launch Phase 1/2 clinical trial of mRNA shingles vaccine; goal is to develop a well-tolerated, highly-effective vaccine that is efficient to produce globally
Published: February 13, 2023 by SeeNews Pharmaceuticals
Pfizer and BioNTech initiate Phase 1/2 study of first mRNA-based shingles vaccine program; globally, about 95% of individuals older than 50 years of age are at risk of developing shingles
Published: February 10, 2023 by BioNTech SE
Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn
Published: February 09, 2023 by Johnson & Johnson Services Inc.
Labcorp to name new clinical development spinoff Fortrea; Fortrea to offer Phase 1-4 clinical trial management, market access , technology solutions to pharmaceutical and biotechnology companies
Published: February 09, 2023 by Business Wire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count